Hologic, Inc. Prepares for Q1 2025 Earnings Release Amid Mixed Analyst Sentiment
Hologic, Inc. (HOLX), based in Marlborough, Massachusetts, boasts a market capitalization of $15.9 billion. The company focuses on developing and supplying diagnostics, medical imaging systems, and surgical products designed to enhance women’s healthcare. Hologic operates in various segments, including Diagnostics, Breast Health, GYN Surgical, and Skeletal Health, aiming to provide advanced solutions for early detection and treatment globally. The firm is scheduled to announce its fiscal Q1 2025 earnings after the market closes on Wednesday, February 5.
Analysts Expect Earnings Growth
In anticipation of this earnings report, analysts predict that Hologic will report a profit of $1.01 per share. This represents a 3.1% increase compared to last year’s $0.98 per share in the same quarter. Hologic has managed to beat Wall Street’s profit expectations in three out of the last four quarters; however, it did fall short once, most recently missing the consensus EPS estimate by almost 1%.
Future Projections and Historical Context
Looking ahead, analysts forecast that for fiscal 2025, HOLX will achieve an EPS of $4.28, reflecting a 4.9% rise from $4.08 in fiscal 2024. Moving into fiscal 2026, EPS growth is estimated to reach 8.9%, climbing to $4.66.
Recent Performance and Stock Trends
HOLX has not kept pace with the broader market over the last year; its shares have declined by 4.6%, in contrast to the S&P 500 Index’s ($SPX) impressive 24.1% gain and the steady performance of the Health Care Select Sector SPDR Fund (XLV).
Investor Concerns Following Q4 Earnings Release
After releasing its Q4 earnings on November 4, HOLX shares dropped by 5.9%. Although the adjusted EPS of $1.01 represented a 13.5% increase from last year, it fell short of expectations, raising questions about future performance. Notably, the Skeletal Health segment experienced a dramatic revenue decline of 54.6% year-over-year, with revenues plummeting to $12.7 million, significantly below the forecast of $28.4 million. Additionally, the cautious fiscal 2025 guidance, predicting revenue growth between 3% – 4% and adjusted EPS estimates ranging from $4.25 to $4.35, contributed to the downturn in stock value.
Analysts Hold a Mixed Yet Positive View
The consensus rating for HOLX is tentatively optimistic, classified as a “Moderate Buy.” Among the 18 analysts covering the stock, seven recommend “Strong Buy,” two suggest “Moderate Buy,” and nine have “Hold” ratings. This analyst outlook is slightly more bullish than it was three months ago, when six analysts issued a “Strong Buy.” Currently, HOLX trades below the average analyst price target of $88.75.
On the date of publication, Sohini Mondal did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
